|

casdatifan Clinical Trials

3 actively recruiting trials across 3 locations

No change since May 2026

Also known as: AB521, C21H17F4NO3S

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

  • Arcus Biosciences, Inc.2
  • Dana-Farber Cancer Institute1

Indications

  • Cancer3
  • Advanced Clear Cell Renal Cell Carcinoma1
  • Metastatic Clear Cell Renal Cell Carcinoma1
  • Renal Carcinoma1
  • Clear Cell Renal Cell Carcinoma1

Birmingham, Alabama1 trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site

Phase 1

Gilbert, Arizona1 trial

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Research Site

Phase 3

Boston, Massachusetts1 trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Beth Israel Deaconess Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.